Suchergebnisse - "Burn, Timothy"

PubPharm (45)

1

Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations

enthalten in: Cancer research and treatment | 2024

von Lindley, A. | Prager, G. | Bitzer, M. | +3

2

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

enthalten in: British journal of cancer | 2022

von Neumann, O. | Burn, T. | Allgäuer, M. | +19

3

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

enthalten in: Nature | 2022

von Zingg, D. | Bhin, J. | Yemelyanenko, J. | +45

ErratumIn: Nature. 2022 Sep;609(7929):E13. - PMID 36050473

4

Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling

enthalten in: The Journal of molecular diagnostics : JMD | 2022

von Silverman, I. | Li, M. | Murugesan, K. | +12

5

Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients

enthalten in: Frontiers in immunology | 2022

von Emtenani, S. | Holtsche, M. | Stahlkopf, R. | +13

6

Discovery of Pemigatinib : A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

enthalten in: Journal of medicinal chemistry | 2021

von Wu, L. | Zhang, C. | He, C. | +22

7

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

enthalten in: Cancer discovery | 2021

von Silverman, I. | Hollebecque, A. | Friboulet, L. | +7

8

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

enthalten in: Clinical immunology (Orlando, Fla.) | 2020

von Yeleswaram, S. | Smith, P. | Burn, T. | +5

9

Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia

enthalten in: Gene | 2020

von Johnston, G. | Ramsey, H. | Liu, Q. | +9

10

Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy

enthalten in: The Journal of pharmacology and experimental therapeutics | 2020

von Shin, N. | Stubbs, M. | Koblish, H. | +34

1
2
3
4
5
Nächster »
[5]